Shinjin Medics Inc. of Goyang at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option
Manufacturers

Shinjin Medics Inc.

B301, 138 Ilsan-ro, Ilsandong-gu, 10442 Goyang
Korea, Republic
Telephone +82 70 82773468
Fax +82 31 9080982
coolpisno1@diakey.com

Hall map

MEDICA 2019 hall map (Hall 1): stand B37

Fairground map

MEDICA 2019 fairground map: Hall 1

Our range of products

Product categories

  • 02  Laboratory Technology
  • 02.09  Laboratory equipment

Laboratory equipment

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing
  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests

Diagnostic rapid tests

Our products

Product category: Immuno assay testing

RIAKEY CA19-9 IRMA Tube II

Intended Use
Immunoradiometric assay for quantitative determination of carbohydrate antigen 19-9(CA19-9) in human serum or plasma

Introduction
Macromolecular tumor markers can be classified into the following major classes: enzymes, hormones and growth factors and their receptors, oncogenic products, viral antigens, oncofetal and surface antigens. With a few exceptions (certain enzymes), most macromolecular tumor markers are glycol-conjugates and a wealth of information is available on these antigens. Therefore, investigations into the expressions of unusual glycoprotein antigens ('markers') associated with tumors and their metastases dominate much of clinical and experimental oncology today. CA19-9 antigen is a kind of carbohydrate antigen, one of important tumor markers. The monoclonal antibody was obtained by Koprowski et al, in 1979 from hybrids of human colon cancer cell line cultured in vitro. The determinant of CA19-9 was proved to be a sialylated lacto-N-fucopentaose Ⅱ. Its biochemical properties are associated with lewis blood group antigens. Analyses of serum samples by several groups have indicated elevated levels of CA19-9 antigen in several types of malignancies, particularly those of pancreas, stomach and colon, but not in sera of normal individuals. CA19-9 antigen was originally identified as a ganglioside isolated from the SW1116 human colorectal carcinoma cell line, while the serum antigen was characterized as a mucin. It can also be detected on mucin in patients' sera. Sources include normal pancreas, bile duct, and gastric, colic, endometric and salivary epithelia. In healthy individuals, the CA19-9 antigen circulates at low levels, normally less than 37U/mL. Elevated levels have been seen in benign inflammatory diseases of the hepatobiliary tract. Studies have also shown that mucin bearing this antigen was more frequently detected in the sera of patients with pancreatic cancer than any other gastrointestinal carcinoma, including colorectal. It is also found in bile duct, ovarian mucinous cystadenocarcinomas and uterine adenocarcinomas.

Principle of the Assay
The assay is a non-competitive immunoradiometric assay (IRMA) method (sandwich principle). The present method employs two monoclonal anti-CA19-9 antibodies which recognize two different epitopes of the molecules. One antibody is absorbed in solid phase (coated tube), the other (labeled with Iodine-125) is used as tracer. The sample to be tested, is incubated in the coated tube, following the incubation, after aspiration and washing, the labeled antibody is added to the coated tubes, where it binds to the solid phase, by means of the antigen in standards and samples. The amount of bound tracer will thus be directly proportional to the antigen concentration. After a further aspiration and washing cycle, the residual radioactivity in the tubes is measured in a gamma counter.

More Less

Product category: Immuno assay testing

RIAKEY NSE IRMA Tube

Intended Use
Immunoradiometric assay for quantitative determination of neuron specific enolase (NSE) in human serum

Principle of the Assay
The present method is based upon two anti-NSE monoclonal antibodies recognizing two different epitopes of the molecule. One antibody is adsorbed to the solid phase (coated tube), the other - labeled with lodine-125 is used as tracer. The sample to be tested is first incubated in the coated tube. Following this incubation and after an aspirating / washing cycle, the labeled antibody is added to each coated tube, where it is bound to the solid phase by means of the antigen in the standards and (if present) in samples. The amount of binding will be directly proportional to the antigen concentration. After tracer incubation, another washing / aspirating cycle will remove any liquid reagent residue.
The radioactivity in the tubes is measured in a gamma counter.

More Less

Product category: Immuno assay testing

RIAKEY hGH IRMA Tube II

Intended Use
RIAKEY hGH IRMA is an in vitro diagnostic assay for the quantitative determination of human growth hormone in serum.

Introduction
Human Growth Hormone (hGH, somatotropin) is the most abundantly secreted, circulating pituitary hormone. It is synthesized by the alpha cells of the anterior pituitary, with molecular weight of about 21.5 kDa. It is composed of a polypeptide chain of 191 amino acids with two disulfide bonds. Endogenous circulating hGH has a short half-life (20-30 minutes) and its serum levels are influenced by several factors: hypoglycemia, exercise and some amino acids (arginine) result in increased hGH levels, while glucose and cortisol tend to inhibit circulating hGH. Somatotropin activity is not directed towards a specific target organ, although hGH receptors have been demonstrated both on liver cells and on lymphocyte membranes. Human Growth Hormone has a direct anti-insulin action, by facilitating amino acid transport as well as free fatty-acid release in muscle tissue. Growth in children is mediated by hGH, which stimulates the liver to produce somatomedins (or insulin-like growth factors, IGF). IGFs are low molecular weight hormones (about 7 kDa) sharing structural homology with pro-insulin. IGFs mostly circulate bound to carrier proteins, which prolong their half-life and make their serum concentrations relatively stable. Quantitative hGH testing is a necessary diagnostic tool for pathologies such as: acromegaly, gigantism, hyposomatism and hypopituitary syndromes. Basal hGH levels are of little relevance, while useful information can be obtained with several dynamic tests like: provocation with arginine, insulin, L-dopa or glucagon, and inhibition by oral glucose intake.

Principle of the Assay
The present method is based upon two anti-hGH monoclonal antibodies recognizing two different epitopes of the molecule. One antibody is adsorbed the solid phase (coated tube), the other - labeled with Iodine 125 - is used as conjugate. During the incubation, the sample to be tested and the labeled antibody are incubated simultaneously in the coated tube forming a "sandwich". At the end of the incubation, the unbound material is removed by an aspiration/washing cycle. The radioactivity in the tubes is measured in a gamma counter.

More Less

About us

Company details

Shin Jin Medics Inc. researches, develops, manufactures, and supplies immunodiagnostic products.

Since 1992, Shin Jin Medics Inc. has been dedicated to everlasting R&D through diagnostic business that today accumulates our own know-how and span advanced technology.

As staple products of Shin Jin Medics Inc. a wide range of diagnostic kits and the instruments such as Gamma counter, Automatic Tube Washer and Incubator are used domestic market as well as world-wide.

We, Shin Jin Medics Inc., will make all possible to become the highest quality diagnostic reagent and instrument manufacturer in Korea, based on the guaranteed quality and technical achievements, and take the lead in global market so that it makes a significant contribution to development of immunodiagnostic and life science technology.

More Less